Gijo Thomas

Gijo Thomas

Auto-generated profile, based on publicly available information

Gijo Thomas

Centre for Heart Rhythm Disorders, University of Adelaide, Adelaide, Australia

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
JNJoan Jacques Noubiap
Joan Jacques Noubiap
JFJohn Fitzgerald
John Fitzgerald
CGCeline Gallagher
Celine Gallagher
GTGijo Thomas
Gijo Thomas
MMMelissa E. Middeldorp
Melissa E. Middeldorp
PSPrashanthan Sanders
Prashanthan Sanders

1 November 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
COCatherine J. O’sHea
Catherine J. O’sHea
MMMelissa E. Middeldorp
Melissa E. Middeldorp
JHJeroen M.H Hendriks
Jeroen M.H Hendriks
ABAnthony G. Brooks
Anthony G. Brooks
CHCurtis Harper
Curtis Harper
PSPrashanthan Sanders
Prashanthan Sanders

2 June 2021 in EP Europace
Verified
Journal Article
Open access
PDF file
COCatherine J O’sHea
Catherine J O’sHea
MMMelissa E Middeldorp
Melissa E Middeldorp
GTGijo Thomas
Gijo Thomas
CHCurtis Harper
Curtis Harper
AEAdrian D Elliott
Adrian D Elliott
PSPrashanthan Sanders
Prashanthan Sanders
The aim of this study is to determine the association between the coronavirus disease 2019 (COVID-19) pandemic and atrial fibrillation (AF) occurrence in individuals with cardiac implantable electronic devices (CIEDs). Multi-centre, observational, cohort study over a 100-day period during the COVID-19 pandemic (COVID-19) in the USA. Remote monitoring was used to assess AF episodes in patients with a CIED (pacemaker or defibrillator; 20 centres, 13 states). For comparison, the identical 100-day period in 2019 was used (Control). The primary outcomes were the AF burden during the COVID-19 pandemic, and the association of the pandemic with AF occurrence, as compared with 1 year prior. The secondary outcome was the association of AF occurrence with per-state COVID-19 prevalence. During COVID-19, 10 346 CIEDs with an atrial lead were monitored. There were 16 570 AF episodes of ≥6 min transmitted (16 events per 1000 patient days) with a significant increase in proportion of patients with AF episodes in high COVID-19 prevalence states compared with low prevalence states [odds ratio 1.34, 95% confidence interval (CI) 1.21–1.48, P < 0.001]. There were significantly more AF episodes during COVID-19 compared with Control [incident rate ratio (IRR) 1.33, 95% CI 1.25–1.40, P < 0.001]. This relationship persisted for AF episodes ≥1 h (IRR 1.65, 95% CI 1.53–1.79, P < 0.001) and ≥6 h (IRR 1.54, 95% CI 1.38–1.73, P < 0.001). During the first 100 days of COVID-19, a 33% increase in AF episodes occurred with a 34% increase in the proportion of patients with AF episodes observed in states with higher COVID-19 prevalence. These findings suggest a possible association between pandemic-associated social disruptions and AF in patients with CIEDs. Australian New Zealand Clinical Trial Registry: ACTRN12620000692932.

1 January 2021 in The American Journal of Cardiology
Verified
Journal Article
Closed access
JNJoan Jacques Noubiap
Joan Jacques Noubiap
TAThomas Agbaedeng
Thomas Agbaedeng
JTJoel Noutakdie Tochie
Joel Noutakdie Tochie
JNJan René Nkeck
Jan René Nkeck
ANAude Laetitia Ndoadoumgue
Aude Laetitia Ndoadoumgue
PSPrashanthan Sanders
Prashanthan Sanders

21 December 2021 in European Heart Journal - Quality of Care and Clinical Outcomes
Verified
Journal Article
Closed access
PDF file
JNJoan Jacques Noubiap
Joan Jacques Noubiap
GTGijo Thomas
Gijo Thomas
TAThomas Agbaedeng
Thomas Agbaedeng
JFJohn L Fitzgerald
John L Fitzgerald
CGCeline Gallagher
Celine Gallagher
PSPrashanthan Sanders
Prashanthan Sanders
This study aimed to investigate the impact of sex on the clinical profile, utilization of rhythm control therapies, cost of hospitalization, length of stay, and in-hospital mortality in patients admitted for atrial fibrillation (AF) in the United States. We used data from the Nationwide Inpatient Sample for the year 2018. Regression analysis was performed to investigate differences between men and women. A P-value ≤ 0.05 was considered significant. We included 82592 patients with a primary diagnosis of of AF 50.8% women. Women were significantly older (mean age 74 vs. 67 years, P < 0.001) and had a higher CHA2DS2-VASc score (median 4 vs. 2, P < 0.001) than men. Women had relatively higher in-hospital mortality (0.9% vs. 0.8%, P = 0.070); however, after adjustment for known risk factors female sex was no longer a predictor of mortality (P = 0.199). In sex-specific regression analyses, increased age, chronic obstructive pulmonary disease, previous stroke, heart failure, and chronic kidney disease were risk factors for in-hospital mortality in both sexes, vascular disease only in women, and race and alcohol abuse only in men. After adjusting for potential confounders, female sex was associated with lower likelihood of receiving catheter ablation [adjusted odds ratio (aOR) 0.69, 95% confidence interval (CI) 0.64–0.74] and electrical cardioversion (aOR 0.69, 95% CI 0.67–0.72), and with longer hospitalization (aOR 1.33, 95% CI 1.28–1.37), whereas sex had no influence on hospitalization costs (P = 0.339). There were differences in the risk profile, management, and outcomes between men and women hospitalized for AF. Further studies are needed to explore why women are treated differently regarding rhythm control procedures.

19 May 2021 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
BPBradley M Pitman
Bradley M Pitman
SCSok-Hui Chew
Sok-Hui Chew
CWChristopher X Wong
Christopher X Wong
AJAmenah Jaghoori
Amenah Jaghoori
SIShinsuke Iwai
Shinsuke Iwai
DLDennis H Lau
Dennis H Lau
Background: Atrial fibrillation (AF) screening using mobile single-lead electrocardiogram (ECG) devices has demonstrated variable sensitivity and specificity. However, limited data exists on the use of such devices in low-resource countries. Objective: The goal of the research was to evaluate the utility of the KardiaMobile device’s (AliveCor Inc) automated algorithm for AF screening in a semirural Ethiopian population. Methods: Analysis was performed on 30-second single-lead ECG tracings obtained using the KardiaMobile device from 1500 TEFF-AF (The Heart of Ethiopia: Focus on Atrial Fibrillation) study participants. We evaluated the performance of the KardiaMobile automated algorithm against cardiologists’ interpretations of 30-second single-lead ECG for AF screening. Results: A total of 1709 single-lead ECG tracings (including repeat tracing on 209 occasions) were analyzed from 1500 Ethiopians (63.53% [953/1500] male, mean age 35 [SD 13] years) who presented for AF screening. Initial successful rhythm decision (normal or possible AF) with one single-lead ECG tracing was lower with the KardiaMobile automated algorithm versus manual verification by cardiologists (1176/1500, 78.40%, vs 1455/1500, 97.00%; P<.001). Repeat single-lead ECG tracings in 209 individuals improved overall rhythm decision, but the KardiaMobile automated algorithm remained inferior (1301/1500, 86.73%, vs 1479/1500, 98.60%; P<.001). The key reasons underlying unsuccessful KardiaMobile automated rhythm determination include poor quality/noisy tracings (214/408, 52.45%), frequent ectopy (22/408, 5.39%), and tachycardia (>100 bpm; 167/408, 40.93%). The sensitivity and specificity of rhythm decision using KardiaMobile automated algorithm were 80.27% (1168/1455) and 82.22% (37/45), respectively. Conclusions: The performance of the KardiaMobile automated algorithm was suboptimal when used for AF screening. However, the KardiaMobile single-lead ECG device remains an excellent AF screening tool with appropriate clinician input and repeat tracing. Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12619001107112; https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=378057&isReview=true